Alnylam and Collaborators at MIT Report New Pre-clinical Research on Systemic Delivery of RNAi Therapeutics
News Dec 30, 2009
Alnylam Pharmaceuticals, Inc. and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.
Lipidoids are lipid-like materials discovered for the delivery of RNAi therapeutics, and were originally described by Alnylam and MIT collaborators. In particular, the new research findings demonstrate the discovery of new lipidoid materials that facilitate significantly improved in vivo potency for RNAi therapeutics.
“We are very encouraged with the substantial progress we and our collaborators have made with lipid nanoparticles (LNPs) based on novel lipid-like materials such as lipidoids.”
“We are very encouraged with the substantial progress we and our collaborators have made with lipid nanoparticles (LNPs) based on novel lipid-like materials such as lipidoids,” said Victor Kotelianski, M.D., Ph.D., D.Sc., Senior Vice President, Distinguished Alnylam Fellow.
“To our knowledge, these new LNP formulations facilitate endogenous liver gene silencing at doses that are orders-of-magnitude lower than those required by previously described siRNA delivery approaches, thereby setting a new standard in potency for the systemic delivery of RNAi therapeutics. In addition, the current study is the first to report on the simultaneous and highly specific RNAi-mediated silencing of as many as five liver targets in vivo, serving as proof of principle that multiple genes involved in similar or divergent biological pathways can be silenced with a single administration of a single drug product. From a therapeutic standpoint, this could enable novel pharmaceutical strategies, where silencing of multiple targets could achieve an enhanced level of efficacy.”
The new pre-clinical data describe a formulation based on a lipidoid known as “C12-200” that was shown to:
• enable gene silencing in vivo in rodents at doses below 0.01 mg/kg;
• demonstrate complete, rapid, and durable gene silencing in rodents as soon as 24 hours with protein levels returning to baseline within 20 to 35 days;
• specifically inhibit expression of as many as five target genes simultaneously after a single injection of an LNP formulation in rodents; and,
• demonstrate potent and selective silencing of the clinically relevant gene transthyretin (TTR) at doses as low as 0.03 mg/kg in non-human primates.
“We are excited by the delivery performance of these new formulations,” said Daniel Anderson, Ph.D. of the David H. Koch Institute for Integrative Cancer Research at MIT.
“This work demonstrates that doses measured in micrograms per kilogram can provide potent gene silencing with RNAi in several species including primates. This greatly improved efficacy allows us to dramatically decrease the dose levels of LNPs, thereby widening the therapeutic index, and also opens the door to formulations that can simultaneously inhibit multiple genes or pathways.”
Lipidoid formulations represent one of several approaches Alnylam is pursuing for systemic delivery of RNAi therapeutics. Additional approaches include other lipid nanoparticles formulations, mimetic lipoprotein particles (MLPs), siRNA conjugation strategies, and single-stranded RNAi, among others.
Alnylam is currently enrolling patients in a Phase I clinical program with its systemic RNAi therapeutic ALN-VSP for the treatment of liver cancers. In addition, Alnylam intends to initiate a Phase I trial in the first half of 2010 for an additional systemic RNAi therapeutic, ALN-TTR for the treatment of TTR-mediated amyloidosis.
ALN-VSP and ALN-TTR both utilize a first generation lipid nanoparticle formulation known as stable nucleic acid-lipid particles (SNALP), developed in collaboration with Tekmira Pharmaceuticals Corp.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
4000-Year Old DNA Helps Track the Spread of Rice Farming in AsiaNews
Rice farming spread far and wide in ancient Southeast Asia, but how it got there has been a mystery. Now, a study of 4000-year-old DNA—a rare find in this region—suggests it came with farmers migrating from China, where rice farming originated.